Chinook Therapeutics Inc Quick Ratio (KDNY) starting from the second quarter 2023 to second quarter 2022, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Chinook Therapeutics Inc   (NASDAQ: KDNY)

Chinook Therapeutics Inc 's Quick Ratio

KDNY's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2023, Quick Ratio fell to 6.5 below Chinook Therapeutics Inc average.

Within Major Pharmaceutical Preparations industry 195 other companies have achieved higher Quick Ratio than Chinook Therapeutics Inc in second quarter 2023. While Quick Ratio total ranking in the second quarter 2023 has deteriorated compared to the prior quarter from 451 to 596.

Explain Quick Ratio?
How much Cash & cash equivalents KDNY´s has?
What are KDNY´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

KDNY Quick Ratio (Jun 30 2023)
Q2		 (Mar 31 2023)
Q1		 (Dec 31 2022)
Q4		 (Sep 30 2022)
Q3		 (Jun 30 2022)
Q2
Y / Y Current Liabilities Change 105.13 % 97.31 % 8.24 % 58.77 % -6.27 %
Y / Y Cash & cash equivalent Change -18.05 % 234.62 % 31.9 % 102.83 % 83.93 %
Quick Ratio MRQ 6.5 8.08 8.72 9.97 16.28
KDNY's Total Ranking # 596 # 451 # 454 # 419 # 424
Seq. Current Liabilities Change 5.36 % -0.02 % 15.93 % 67.98 % 1.34 %
Seq. Cash & cash equivalent Change -15.19 % -7.39 % 1.35 % 2.94 % 246.31 %



Quick Ratio second quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 196
Healthcare Sector # 327
Overall Market # 596


Quick Ratio Statistics
High Average Low
16.28 10.57 3.69
(Jun 30 2022)   (Mar 31 2015)




Financial Statements
Chinook Therapeutics Inc 's Current Liabilities $ 46 Millions Visit KDNY's Balance sheet
Chinook Therapeutics Inc 's Cash & cash equivalent $ 297 Millions Visit KDNY's Balance sheet
Source of KDNY's Sales Visit KDNY's Sales by Geography


Cumulative Chinook Therapeutics Inc 's Quick Ratio

KDNY's Quick Ratio for the trailling 12 Months

KDNY Quick Ratio

 (Jun 30 2023)
12 Months		 (Mar 31 2023)
12 Months		 (Dec 31 2022)
12 Months		 (Sep 30 2022)
12 Months		 (Jun 30 2022)
12 Months
Y / Y Current Liabilities TTM Growth 57.42 % 33.87 % 11.27 % 21.01 % 17.43 %
Y / Y Cash & cash equivalent TTM Growth 49.13 % 89.54 % 37.33 % 32.93 % 22.59 %
Quick Ratio TTM 8.24 10 9.75 9.26 8.69
Total Ranking TTM # 3597 # 3181 # 105 # 3499 # 3487
Seq. Current Liabilities TTM Growth 15.99 % 17.1 % 2.71 % 12.84 % -1.36 %
Seq. Cash & cash equivalent TTM Growth -4.47 % 20.15 % 8.11 % 20.17 % 21.41 %

Quick ratio ranking by company, industry and sector >> Back to KDNY Financial Strength Comparisons >> Go to Compare KDNY Quick Ratio to its Competitors

On the trailing twelve months basis Due to rise in Current Liabilities in the Q2 2023 to $45.70 millions, cumulative Quick Ratio decreased to 8.24 below the Chinook Therapeutics Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 527 other companies have achieved higher Quick Ratio than Chinook Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2023 from 3181 to 3597.

Explain Quick Ratio?
How much Cash & cash equivalents KDNY´s has?
What are KDNY´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 528
Healthcare Sector # 1040
Within the Market # 3597


trailing twelve months Quick Ratio Statistics
High Average Low
11.84 9.04 7.03
(Jun 30 2017)   (Jun 30 2023)




Companies with similar Quick Ratio in the quarter ending Jun 30 2023, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2023 MRQ Cash & cash equivalentJun 30 2023 MRQ Current Liabilities
Savara Inc   17.87 $ 105.179  Millions$ 5.885  Millions
Lyell Immunopharma Inc   17.32 $ 595.748  Millions$ 34.390  Millions
Kezar Life Sciences Inc   17.22 $ 236.589  Millions$ 13.737  Millions
Agios Pharmaceuticals Inc   17.21 $ 702.566  Millions$ 40.815  Millions
Rallybio Corporation  17.12 $ 137.838  Millions$ 8.053  Millions
Janux Therapeutics Inc   16.94 $ 303.289  Millions$ 17.904  Millions
Shuttle Pharmaceuticals Holdings Inc   16.92 $ 8.351  Millions$ 0.494  Millions
Ventyx Biosciences Inc   16.58 $ 332.252  Millions$ 20.034  Millions
Cymabay Therapeutics Inc   16.38 $ 213.844  Millions$ 13.056  Millions
Pmv Pharmaceuticals Inc   16.34 $ 187.087  Millions$ 11.447  Millions
Mineralys Therapeutics Inc   16.29 $ 101.140  Millions$ 6.207  Millions
Tenax Therapeutics Inc   16.26 $ 13.394  Millions$ 0.824  Millions
Scpharmaceuticals Inc   16.16 $ 102.877  Millions$ 6.368  Millions
Lantern Pharma Inc   15.90 $ 47.949  Millions$ 3.016  Millions
Biomea Fusion Inc   15.53 $ 222.908  Millions$ 14.357  Millions
Pyxis Oncology Inc   15.46 $ 142.663  Millions$ 9.225  Millions
Nanoviricides inc   15.25 $ 8.150  Millions$ 0.534  Millions
Dynavax Technologies Corporation  15.19 $ 681.525  Millions$ 44.862  Millions
Landos Biopharma Inc   14.84 $ 44.736  Millions$ 3.015  Millions
Sensei Biotherapeutics Inc   14.72 $ 78.840  Millions$ 5.357  Millions
Eledon Pharmaceuticals Inc   14.57 $ 71.378  Millions$ 4.900  Millions
Larimar Therapeutics Inc   14.32 $ 104.200  Millions$ 7.275  Millions
Lipocine Inc   14.11 $ 25.790  Millions$ 1.827  Millions
Verve Therapeutics Inc   14.00 $ 462.476  Millions$ 33.031  Millions
Anixa Biosciences Inc   13.75 $ 25.534  Millions$ 1.857  Millions
Artelo Biosciences Inc   13.72 $ 8.272  Millions$ 0.603  Millions
Dianthus Therapeutics Inc   13.69 $ 55.240  Millions$ 4.034  Millions
Erasca Inc   13.62 $ 317.245  Millions$ 23.292  Millions
Syndax Pharmaceuticals Inc   13.46 $ 406.024  Millions$ 30.168  Millions
Annovis Bio Inc   13.41 $ 15.725  Millions$ 1.173  Millions

Date modified: 2026-09-18T13:11:05+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.